No Data
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
OpenAI Project to Improve ChatGPT Behind Schedule as Costs Soar: Report
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Notable Analyst Calls This Week: Tesla, Zoom and Micron Stocks Among Top Picks